The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Examining the Time to Improvement of Sleep Interference With Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy and Postherpetic Neuralgia
Abstract
Pregabalin has been shown to be a safe, effective treatment for neuropathic pain associated with painful diabetic peripheral neuropathy (DPN) or postherpetic neuralgia (PHN), with average time to reduction in pain of 2 days. Pain-related sleep interference is commonly reported in both painful DPN and PHN. These post hoc analyses examined the time to improvement in sleep with pregabalin in patients with painful DPN or PHN, measured by reduction in daily sleep interference (DSI) scores on an 11-point numeric rating scale. A total of 4527 patients from 16 placebo-controlled trials of pregabalin for treatment of painful DPN or PHN were included in the analysis. In these trials, there were a total of 16 pregabalin treatment arms for painful DPN (75-600 mg/d), 10 for PHN (150-600 mg/d), and 3 for painful DPN/PHN (150-600 mg/d). Time to improvement in DSI scores was calculated for all treatment arms that demonstrated statistically significant reductions in DSI scores during the first 14 days of treatment compared with placebo (23 of 29; 79.3%) and was defined as the first day DSI scores for that day and the following day were significantly lower than placebo (P < 0.001). Mean (SD) time to improvement in DSI scores was 1.6 (1.3) days. Sustained improvement (≥1-point improvement in mean DSI score) was seen significantly earlier for pregabalin DSI responders than patients receiving placebo. These findings demonstrate that statistically significant and sustained improvement in sleep occurs rapidly (within 1 day for some patients) in response to treatment with pregabalin.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“At present, among pharmacological options, pregabalin588–598 and duloxetine594,595,599,600 are oral agents that have received regulatory approval for the treatment of neuropathic pain associated with DPN by the FDA and are effective for DPN pain reduction when using patient-reported outcomes.547”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [593]
Citations
Cites
Treede (2008) · doi:10.1212/01.wnl.0000282763.29778.59 · Cited by 2,746
Boulton, A. J. M., Vinik, A. I., Arezzo, J. C., Bril, V., Feldman, E. L., Freeman, R., Malik, R. A., Maser, R. E., Sosenko, J. M., & Ziegler, D. (2005) · Diabetes Care · doi:10.2337/diacare.28.4.956 · Cited by 1,859
Vascular risk factors and diabetic neuropathy
Tesfaye, S., Chaturvedi, N., Eaton, S. E. M., Ward, J. D., Manes, C., Ionescu-Tirgoviste, C., Witte, D. R., & Fuller, J. H. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa032782 · Cited by 1,323
Smith, M. T., & Haythornthwaite, J. A. (2004) · Sleep Medicine Reviews · doi:10.1016/s1087-0792(03)00044-3 · Cited by 914 · cited 3×
“Sleep interference has a substantial negative impact on patients’ quality of life and may also increase a patient’s sensitivity to pain.(19) Thus, the rapid reduction in sleep interference observed with Table 4.”
BackgroundInfluentialPregabalin for the treatment of postherpetic neuralgia: A randomized, placebo-controlled trial
Dworkin, R. H., Corbin, A. E., Young, J. P., Sharma, U., LaMoreaux, L., Bockbrader, H., Garofalo, E. A., & Poole, R. M. (2003) · Neurology · doi:10.1212/01.wnl.0000055433.55136.55 · Cited by 768
The Prevalence, Severity, and Impact of Painful Diabetic Peripheral Neuropathy in Type 2 Diabetes
Davies, M., Brophy, S., Williams, R., & Taylor, A. (2006) · Diabetes Care · doi:10.2337/dc05-2228 · Cited by 746
Rosenstock, J., Tuchman, M., LaMoreaux, L., & Sharma, U. (2004) · Pain · doi:10.1016/j.pain.2004.05.001 · Cited by 725
Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life
Galer, B. S., Gianas, A., & Jensen, M. P. (2000) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(99)00112-6 · Cited by 601
Field, M. J., Cox, P. J., Stott, E., Melrose, H., Offord, J., Su, T.-Z., Bramwell, S., Corradini, L., England, S., Winks, J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409066103 · Cited by 591
Freynhagen, R., Strojek, K., Griesing, T., Whalen, E., & Balkenohl, M. (2005) · Pain · doi:10.1016/j.pain.2005.02.032 · Cited by 572
Research works printed but not linked: 1
- Hoffman, 2010, Dukes EM, et al.., How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy Pain, 149, 194
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Merante, D., Rosenstock, J., Sharma, U., Feins, K., Hsu, C., Vinik, A. I., & on behalf of the DS-5565-A-U201 US Phase 2 Study Investigators (2017) · Pain Medicine · doi:10.1093/pm/pnw342 · Cited by 38
Sadosky, A., Taguchi, T., Igarashi, A., WATT, S. J., Parsons, B., Hayakawa, K., Nozawa, K., Yoshiyama, T., Ebata, N., & Fujii, K. (2015) · Journal of Pain Research · doi:10.2147/jpr.s88642 · Cited by 37
Self-citationLiu, Q., Chen, H., Xi, L., Hong, Z., He, L., Fu, Y., Fang, H., Shang, N., Yan, P., & Fan, D. (2015) · Pain Practice · doi:10.1111/papr.12413 · Cited by 32
The Efficacy of Pregabalin in the Treatment of Prediabetic Neuropathic Pain
González‐Duarte, A., Lem‐Carrillo, M., Díaz‐Díaz, E., Castillo, C., & Cárdenas‐Soto, K. (2015) · Clinical Journal of Pain · doi:10.1097/ajp.0000000000000339 · Cited by 17
Metadata
- Authors
- Parsons, B., Emir, B., & Knapp, L.
- Affiliations
- Pfizer (United States) (US)
- Corresponding author
- Parsons, Bruce
- Venue
- American Journal of Therapeutics
- Published
- 2015-07
- Volume
- 22
- Issue
- 4
- Pages
- 257-268
- ISSN
- 1075-2765 (ISSN-L)
- OpenAlex
- W2094962188
- Cited by
- 20
- References
- 38
- Citations by year
- 2026: 2 · 2023: 2 · 2022: 1 · 2020: 1 · 2019: 2 · 2018: 2 · 2017: 5 · 2016: 2 · 2015: 3
- FWCI
- 2.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Keywords
- pregabalin, sleep interference, diabetic neuropathic pain, postherpetic neuralgia, neuropathic pain, sustained improvement
- MeSH terms
- Pregabalin, Adult, Aged, Aged, 80 and over, Analgesics, Diabetic Neuropathies, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Sleep Wake Disorders, Time Factors, Treatment Outcome, Neuralgia, Postherpetic, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Examining the Time to Improvement of Sleep Interference With Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy and Postherpetic Neuralgia. https://app.cochat.ai/papers/10.1097/mjt.0000000000000100
- The paper
- Parsons, B., Emir, B., & Knapp, L. (2015). Examining the Time to Improvement of Sleep Interference With Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy and Postherpetic Neuralgia. American Journal of Therapeutics. https://doi.org/10.1097/mjt.0000000000000100
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.